Description

Curis Lifesciences Limited equity shares admitted to trading on NSE EMERGE SME Platform with effect from November 14, 2025 under Trade for Trade Surveillance Segment.

Summary

National Stock Exchange has listed equity shares of Curis Lifesciences Limited on the EMERGE SME Platform effective November 14, 2025. The stock will trade under symbol ‘CURIS’ in Series ‘ST’ (Trade for Trade Surveillance Segment with Settlement Type ‘W’) initially, with subsequent shift to Series ‘SM’ (Normal Rolling Segment). The IPO was priced at Rs. 128 per share with face value of Rs. 10. Total issue comprises 8,084,434 equity shares with market lot size of 1,000 shares.

Key Points

  • Symbol: CURIS, ISIN: INE1BZN01016
  • Trading commences: November 14, 2025 on NSE EMERGE SME Platform
  • Initial trading in Series ‘ST’ (Trade for Trade Surveillance Segment, Settlement Type ‘W’)
  • Will subsequently shift to Series ‘SM’ (Normal Rolling Segment, Settlement Type ‘N’)
  • IPO Price: Rs. 128 per share, Face Value: Rs. 10
  • Total issued shares: 8,084,434 equity shares
  • Market lot size: 1,000 equity shares
  • Market Maker Maximum Permissible Spread: Within 10%
  • Part of pre-open session for IPO and Other category scrips
  • Available for trading in continuous market

Regulatory Changes

None. This circular notifies a new listing in compliance with existing regulations:

  • National Stock Exchange (Capital Market) Trading Regulations Part A, Regulation 3.1.1 (admission to dealings)
  • National Stock Exchange (Capital Market) Trading Regulations Part A, Regulation 2.5.5 (lot sizes)
  • SEBI circular CIR/MRD/DP/01/2012 & CIR/MRD/DP/02/2012 dated January 20, 2012 (pre-open session)
  • Exchange Circular NSE/CMTR/37202 dated March 14, 2018 (continuous market trading)

Compliance Requirements

  • Members must identify the security by designated code ‘CURIS’
  • Trading must be in specified lot size of 1,000 equity shares
  • Market makers must maintain spread within 10%
  • Trade for Trade settlement applies initially (Series ‘ST’, Settlement Type ‘W’)
  • Lock-in provisions apply as per Annexure I (distinctive number ranges specified)
  • Company Secretary and Compliance Officer: Mr. Nikhil Purohit (cs@curisls.com)

Important Dates

  • Circular Date: November 13, 2025
  • Trading Commencement: November 14, 2025
  • Financial Year: April 2025 - March 2026

Impact Assessment

Market Impact: Low to medium. This is an SME listing on the EMERGE platform, affecting primarily SME investors and market makers. The Trade for Trade surveillance segment placement indicates enhanced monitoring.

Operational Impact: Market participants trading in SME segment need to note the new listing. Initial T4T settlement requires delivery-based trading only, limiting speculation. Market makers (RS Wealth Management Private Limited) must maintain liquidity within specified spread limits.

Investor Impact: SME investors gain access to new pharmaceutical/lifesciences company. Higher lot size (1,000 shares at Rs. 128 = Rs. 1,28,000 minimum investment) creates entry barrier. Lock-in provisions apply to promoter/pre-IPO holdings as per Annexure I.

Company Details

Registered Office: Curis Lifesciences Limited PF-23, GIDC Sanand - II, Industrial Estate Ahmedabad, Sanand, Gujarat - 382110 Tel: +91 99045 22543 Email: cs@curisls.com Website: www.curisls.com

Registrar & Transfer Agent: MUFG Intime India Private Limited C-101, 247 Park, L B S Marg, Vikhroli West Mumbai - 400083 Tel: +91 810 811 4949 Email: curislifesciences.smeipo@in.mpms.mufg.com

Market Maker: RS Wealth Management Private Limited 606, Pearls Best Heights-II, Plot No C-9 Netaji Subhash Place, Pitampura New Delhi - 110034 Tel: 011-40821500 Email: compliance@rswealth.in

Impact Justification

New SME listing on EMERGE platform with Trade for Trade surveillance measures. Impacts SME investors and market makers but limited broader market significance.